S-23 (drug) explained

S-23 is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc as a potential male hormonal contraceptive. It binds to the androgen receptor more strongly than older drugs such as andarine with a Ki of 1.7 nM, and in animal studies it showed both a good ratio of anabolic to androgenic effects, and dose-dependent suppression of spermatogenesis with spontaneous recovery after cessation of treatment.[1] [2]

Notes and References

  1. Marhefka CA, Gao W, Chung K, Kim J, He Y, Yin D, Bohl C, Dalton JT, Miller DD . 6 . Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators . Journal of Medicinal Chemistry . 47 . 4 . 993–8 . February 2004 . 14761201 . 2040239 . 10.1021/jm030336u .
  2. Jones A, Chen J, Hwang DJ, Miller DD, Dalton JT . Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception . Endocrinology . 150 . 1 . 385–95 . January 2009 . 18772237 . 2630904 . 10.1210/en.2008-0674 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "S-23 (drug)".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.